Sio Capital Management LLC Purchases 37,558 Shares of Artivion, Inc. $AORT

by · The Markets Daily

Sio Capital Management LLC grew its holdings in Artivion, Inc. (NYSE:AORT – Free Report) by 31.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 158,736 shares of the company’s stock after acquiring an additional 37,558 shares during the quarter. Artivion accounts for approximately 1.9% of Sio Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Sio Capital Management LLC owned about 0.34% of Artivion worth $4,937,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of AORT. Quadrature Capital Ltd acquired a new stake in Artivion in the 2nd quarter worth about $342,000. XTX Topco Ltd bought a new position in shares of Artivion during the second quarter worth approximately $1,590,000. Prudential Financial Inc. raised its position in shares of Artivion by 5.5% in the second quarter. Prudential Financial Inc. now owns 39,893 shares of the company’s stock valued at $1,241,000 after buying an additional 2,072 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Artivion by 3.3% in the second quarter. Rhumbline Advisers now owns 110,862 shares of the company’s stock valued at $3,448,000 after buying an additional 3,542 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Artivion by 1.9% in the second quarter. Franklin Resources Inc. now owns 29,263 shares of the company’s stock valued at $910,000 after buying an additional 533 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Amy Horton sold 6,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $45.73, for a total transaction of $274,380.00. Following the sale, the chief accounting officer owned 135,380 shares in the company, valued at $6,190,927.40. The trade was a 4.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 6,394 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $45.17, for a total value of $288,816.98. Following the completion of the transaction, the senior vice president directly owned 163,408 shares of the company’s stock, valued at approximately $7,381,139.36. The trade was a 3.77% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 191,703 shares of company stock valued at $8,669,234. 7.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on AORT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Citizens Jmp raised their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Stifel Nicolaus increased their price objective on shares of Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Finally, Needham & Company LLC boosted their target price on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $49.11.

Get Our Latest Stock Report on Artivion

Artivion Stock Down 1.8%

Shares of NYSE AORT opened at $45.83 on Tuesday. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -109.12 and a beta of 1.65. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.04. The stock has a 50-day moving average price of $43.68 and a two-hundred day moving average price of $37.78.

Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

About Artivion

(Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Recommended Stories

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).